Ansun BioPharma
PrivateLast Round
Series B
Oct 1, 2019
Total Funding Raised
$215M
Momentum Score
50 /100
Company Overview
Ansun Biopharma is a biopharmaceutical company focused on developing therapies that prevent, treat, and cure challenging human diseases through a host-directed anti-viral biological product targeting respiratory viral infections like influenza and metapneumovirus.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2G
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ansun BioPharma Comps
Public and private peers based on sector, stage, and business model.
Ansun BioPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 1, 2019 | ||||
| Series A | May 14, 2018 | ||||
| Grant | Sep 1, 2006 |
Ansun BioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series B, Series A |
| Bencao Capital | Series B |
| NIH RADx | Grant |
| Next Capital | Series B |
| Junson Capital | Series B |
| LYFE Capital | Series B, Series A |
| Oceanpine Capital | Series A, Series B |
Ansun BioPharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ansun BioPharma's valuation, stock price, and market status.
